Furthermore, regarding the effects of each TNF-α inhibitor on the levels of aggrecan turnover biomarkers, i.e., CS846 and AGC, in female RA patients, our results demonstrate the superiority of etanercept therapy in preventing cartilage damage when compared to adalimumab. Here, TNF is linked to rheumatoid arthritis.